Research

Clinical Pipeline

Anasonic is dedicated to advancing its Low-Intensity Pliant Ultrasound (LIPUS) technology through rigorous clinical research. Our clinical pipeline reflects our commitment to validating the safety and efficacy of LIPUS for chronic kidney disease (CKD) treatment and expanding its applications to other medical conditions.

Preclinical Research
Jump To
Clinical Trials
Jump To
Future Directions
Jump To

Preclinical Research


Several peer-reviewed papers have been published detailing the preclinical results, supporting the potential of LIPUS as a viable CKD treatment.

Key Finding

Improved GFR

Animal models demonstrated significant improvements in Glomerular Filtration Rate (GFR), indicating enhanced kidney function.

Key Finding

Reduced Inflammation

LIPUS treatment resulted in decreased levels of inflammatory markers in kidney tissues.

Key Finding

Oxidative Stress Reduction

The therapy increased antioxidant enzyme activity, reducing oxidative stress and protecting kidney cells from damage.

Clinical Trials

Phase I/II Trials

Exploratory Clinical Trials

  • Objective: To evaluate the safety, tolerability, and preliminary efficacy of LIPUS in human CKD patients.
  • Design: Open-label, single-arm studies involving a small group of patients to monitor immediate and short-term effects of the therapy.
  • Location: Seoul St. Mary’s Hospital

Milestone:

  • Clinical trial approval by MFDS (JUL. 2024)
  • IRB approval for clinical trials at Seoul St. Mary’s Hospital and Eunpyeong St. Mary’s Hospital (JUN. 2024)
  • Completion of the first exploratory clinical trial (JUN. 2025)
  • Completion of the second confirmatory/approval clinical trial (JUN. 2026)
Phase III Trials

Confirmatory Clinical Trials

  • Objective: To confirm the efficacy and safety of LIPUS in a larger, more diverse patient population and to provide robust data for regulatory submissions.
  • Design: Multicenter, randomized, controlled trials comparing LIPUS treatment with standard care.
  • Locations: Multiple leading medical centers worldwide

Trial Phases

  • Exploratory Trials (2024): Initial human trials to evaluate safety and efficacy, showing promising results in improving GFR and reducing inflammation.
  • Confirmatory Trials (2025-2026): Larger-scale trials aimed at confirming the findings from exploratory trials and securing regulatory approval for widespread clinical use.

Future Directions

Ongoing and Planned Studies

Anasonic is continuously expanding its research efforts to explore new applications and further validate LIPUS technology. Future studies will focus on:

Expansion to Other Conditions
  • Investigating the efficacy of LIPUS in treating other chronic conditions such as cardiovascular diseases and neurodegenerative disorders.
Long-Term Efficacy and Safety
  • Conducting long-term follow-up studies to ensure sustained benefits and monitor any potential late-onset effects.
Pediatric Trials
  • Exploring the use of LIPUS in pediatric patients with CKD to provide early intervention and improve long-term outcomes.

Regulatory Approvals

Anasonic is committed to achieving regulatory approvals for LIPUS technology across multiple regions.


We are working closely with regulatory agencies to meet the necessary standards and bring this innovative treatment to patients worldwide.